Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $140,853.67 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 4,267 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total value of $140,853.67. Following the sale, the general counsel owned 33,464 shares of the company’s stock, valued at approximately $1,104,646.64. The trade was a 11.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, March 18th, Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total value of $145,041.52.

Stoke Therapeutics Stock Up 1.0%

Shares of NASDAQ STOK opened at $33.51 on Friday. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $40.22. The company has a market cap of $1.98 billion, a P/E ratio of 50.01 and a beta of 1.07. The business’s 50 day moving average is $32.61 and its two-hundred day moving average is $30.09.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of STOK. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the fourth quarter valued at $26,000. Harbour Investments Inc. boosted its stake in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares in the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics in the 3rd quarter valued at $41,000. BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on STOK. Needham & Company LLC boosted their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Canaccord Genuity Group boosted their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.